Halozyme Therapeutics Inc (HALO)
Cash conversion cycle
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 324.80 | 242.12 | 262.34 | 241.69 | 511.28 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — |
| Cash conversion cycle | days | 324.80 | 242.12 | 262.34 | 241.69 | 511.28 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 324.80 + — – —
= 324.80
The cash conversion cycle of Halozyme Therapeutics Inc has demonstrated fluctuations over the five-year period from 2020 to 2024.
In 2020, the company had a relatively long cash conversion cycle of 511.28 days, indicating that it took a significant amount of time for the company to convert its investments in inventory and other resources into cash inflows.
The cash conversion cycle then significantly decreased to 241.69 days by the end of 2021. This improvement suggests that the company streamlined its operations to manage its working capital more efficiently, reducing the time it took to convert its investments into cash.
However, by the end of 2022, the cash conversion cycle increased slightly to 262.34 days, indicating a potential slowdown in the efficiency of the company's working capital management.
In 2023, the cash conversion cycle decreased to 242.12 days, showing a partial recovery from the increase in the previous year.
By the end of 2024, the cash conversion cycle increased significantly to 324.80 days, suggesting a longer time taken for the company to convert its investments into cash, which may raise concerns about working capital management or operational efficiency.
Overall, fluctuations in the cash conversion cycle of Halozyme Therapeutics Inc over the five-year period may indicate varying levels of efficiency in managing working capital and converting investments into cash inflows.
Peer comparison
Dec 31, 2024